cm336
mAbexperimentalBi-specific
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
1
Phase 4
0
Earliest trial started Apr 15, 2022 (NCT05299424)
Timeline
Indications
Mechanism of action
CD3E activator
- BCMAINHIBITOR
BCMA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07175493 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2025 | Keymed Biosciences Co.Ltd |
| NCT07181239 | Phase 3 | Sep 30, 2025 | Chinese Academy of Medical Sciences, Keymed Biosciences Co.Ltd |
| NCT07151690 | Phase 2 | Sep 4, 2025 | China Academy of Chinese Medical Sciences |
| NCT07115667 | Phase 2 | Aug 25, 2025 | China Academy of Chinese Medical Sciences |
| NCT07115654 | Phase 2 | Aug 10, 2025 | China Academy of Chinese Medical Sciences |
| NCT07039578 | Phase 2 | Jul 25, 2025 | China Academy of Chinese Medical Sciences, Chinese Academy of Medical Sciences, Keymed Biosciences Co.Ltd |
| NCT06900010 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2025 | Shandong first medical University |
| NCT06799611 | Phase 2 | Mar 3, 2025 | China Academy of Chinese Medical Sciences |
| NCT06745687 | N/A | Dec 30, 2024 | China Academy of Chinese Medical Sciences, Keymed Biosciences Co.Ltd |
| NCT05299424 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2022 | Keymed Biosciences Co.Ltd |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 6 | 5 | 2 | 2024 |
| Keymed Biosciences Co.Ltd | For profit | 5 | 4 | 3 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2025 |
| Shandong first medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1